AOTI (LSE:AOTI), Inc., the US medical technology company quoted on London's AIM market, has drawn attention in 2026 after securing what it called a "transformational milestone" in US reimbursement and reporting first-half growth ahead of guidance. The company's first-half margins beat expectations as an overhaul of its sales operations began to gain traction. Together with earlier coverage decisions from US healthcare payers, the news has made AOTI one of the more closely followed healthcare names on the FTSE AIM All Share Index.

What the Company Does

AOTI develops and sells TWO2, a topical wound oxygen therapy system designed to treat chronic wounds such as diabetic foot ulcers. The therapy delivers oxygen directly to the wound surface and is intended for home use. The company, which operates primarily in the United States, joined AIM in a listing celebrated by the London Stock Exchange. The TWO2 system has reached a milestone of one million treatments, and in 2025 AOTI expanded US market access with a California provider identification.

Latest Developments

The most significant development this year was a decision by the US Centers for Medicare and Medicaid Services. AOTI hailed the "transformational milestone" of a CMS decision, and the Medicare coverage determination lifted the stock among the week's AIM gainers. AOTI has also gained US medical payment approvals. Separately, the shares surged after a Medicaid decision seen as offering potential to improve growth rates.

Reimbursement is central to the company's prospects, because coverage by public payers can widen the number of patients able to access the therapy and support adoption by clinicians. AOTI followed the CMS announcement with a trading statement in which the company highlighted solid top-line growth.

Financial Picture

AOTI's growth in the first half of 2026 beat guidance, and margins came in ahead of expectations as the company's sales restructuring started to show results. The company had earlier published its 2025 Annual Report and notice of AGM. Precise revenue, profit and cash figures were not available at the time of writing, so investors may wish to consult the original announcements. No Dividend was identified at the time of writing, which is consistent with a growth-focused medical technology company.

Sector and index Context

Chronic wound care is a large and costly area for health systems, particularly given the prevalence of diabetes, and payers increasingly look for treatments that can reduce amputations and hospital admissions. For medical device companies, reimbursement decisions often determine the pace of commercial uptake. Within the FTSE AIM All Share Index, AOTI is one of a number of US-based companies that have chosen a London listing, and its shares have shown sharp moves on regulatory and reimbursement news.

Key Risks

The main risks include the speed at which Medicare and Medicaid coverage translates into prescriptions and revenue, potential changes to reimbursement rates or policies, and competition from other advanced wound care products. Execution of the sales overhaul remains important, and any shortfall against guidance could weigh on sentiment. The company is also exposed to US healthcare regulation and currency movements for UK-based investors.

What to Watch Next

Investors will look for evidence of patient Volume growth following the CMS decision, further payer coverage wins, and progress in the restructured sales organisation. Full-year trading updates, Margin trends and any additional clinical evidence supporting TWO2 are likely to be key indicators for the remainder of 2026.